Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?


Dec. 4 2020, Updated 10:52 a.m. ET

Increased sales

Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US. Eylea’s net product sales for Regeneron amounted to $2.7 billion in fiscal 2015, and the global net sales for the product during fiscal 2015 stood at $4.1 billion, 47% over fiscal 2014. On a quarterly basis, Eylea’s revenue grew by 1.6% during 4Q15.

Article continues below advertisement

Recent Eylea news

In October 2015, Eylea received marketing authorization from the European Commission for treating visual impairment caused by myopic choroidal neovascularization. In 1Q16, Regeneron is planning to initiate Panorama, a phase 3 trial for patients with diabetic retinopathy without diabetic macular edema.

But multiple trials are being conducted in various phases for Eylea. The drug has become a leading brand in the market for anti-vascular endothelial growth factor therapy. Major competitors for the drug include Novartis’s (NVS) Visudyne, Roche’s (RHHBY) Lucentis and Avastin, and Pfizer’s (PFE) Macugen. In 2016, Regeneron expects Eylea’s US net product sales to grow by 20% over 2015 sales.

To diversify the risk of investing directly in the equity of Regeneron Pharmaceuticals, investors can look for options such as the iShares Nasdaq Biotechnology ETF (IBB), which has about 5.5% of its total holdings in Regeneron Pharmaceuticals.


Latest Novartis AG News and Updates

    Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.